Evidence map›Paper›PMID 24731657›Full record

ReviewThe lancet. Diabetes & endocrinology2014

The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.

Robert A Hegele, Henry N Ginsberg, M John Chapman, Børge G Nordestgaard, Jan Albert Kuivenhoven, Maurizio Averna, Jan Borén, Eric Bruckert, Alberico L Catapano, Olivier S Descamps and 16 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The lancet. Diabetes & endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 214 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
214citing papers in PubMed, 7 pooled it
24.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

214 citing papers in PubMed, 7 syntheses or guidelines pooled it, 622 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Guideline
  6. Pooled it
  7. Guideline
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Article
  16. Article
  17. Article
  18. Dietary Interventions for Hypertriglyceridemia.Current atherosclerosis reports · 2026
    Review
  19. Review
  20. Article

154 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 19 institutions in 14 countries.

Robert A HegeleDepartment of Medicine, Western University, London, ON, Canada. Electronic address: hegele@robarts.ca.
Henry N GinsbergIrving Institute for Clinical and Translational Research, Columbia University, New York, NY, USA.
M John ChapmanDyslipidaemia and Atherosclerosis Research Unit, INSERM U939, Pitié-Salpêtrière University Hospital, Paris, France.
Børge G NordestgaardDepartment of Diagnostic Sciences, Herlev Hospital, University of Copenhagen, Denmark.
Jan Albert KuivenhovenDepartment of Molecular Genetics, University Medical Center Groningen, University of Groningen, Netherlands.
Maurizio AvernaDepartment of Internal Medicine, University of Palermo, Palermo, Italy.
Jan BorénStrategic Research Center, Sahlgrenska Center for Cardiovascular and Metabolic Research, University of Gothenburg, Gothenburg, Sweden.
Eric BruckertDepartment of Endocrinology and Metabolism, Endocrinology and Cardiovascular Disease Prevention, Hôpital Pitié-Salpêtrière, Paris, France.
Alberico L CatapanoDepartment of Pharmacological Sciences, University of Milan and Multimedica IRCSS, Milan, Italy.
Olivier S DescampsCentre de Recherche Médicale, Lipid Clinic, Hopital de Jolimont, Haine Saint-Paul, Belgium.
G Kees HovinghDepartment of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Steve E HumphriesCentre for Cardiovascular Genetics, Institute of Cardiovascular Science, University College London, London, UK.
Petri T KovanenWihuri Research Institute, Helsinki, Finland.
Luis MasanaVascular Medicine and Metabolism Unit, Sant Joan University Hospital, Universitat Rovira & Virgili, IISPV, CIBERDEM, Reus, Spain.
Päivi PajukantaDepartment of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Klaus G ParhoferDepartment of Endocrinology and Metabolism, University of Munich, Munich, Germany.
Frederick J RaalDivision of Endocrinology and Metabolism, Director of the Carbohydrate and Lipid Metabolism Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
Kausik K RayCardiovascular Sciences Research Centre, St George's Hospital NHS Trust, London, UK.
Raul D SantosLipid Clinic Heart Institute (InCor), University of São Paulo Medical School Hospital, São Paulo, Brazil.
Anton F H StalenhoefDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Erik StroesDepartment of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Marja-Riitta TaskinenCardiovascular Research Group, Heart and Lung Centre, Helsinki University Central Hospital and Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland.
Anne Tybjærg-HansenDepartment of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Gerald F WattsSchool of Medicine and Pharmacology, Royal Perth Hospital Unit, The University of Western Australia, Perth, WA, Australia.
Olov WiklundDepartment of Cardiology, Wallenberg Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden.
European Atherosclerosis Society Consensus Panel
Academic Medical Center · NLUniversity of Copenhagen · DKCentro de Investigación Biomédica en Red · ESColumbia University · USHôpital de Jolimont · BEHospital São Paulo · BRLudwig-Maximilians-Universität München · DERadboud University Medical Center · NLRoyal Perth Hospital · AUSorbonne Université · FRSt George's Hospital · GBUniversity College London · GBUniversity of California, Los Angeles · USUniversity of Gothenburg · SEUniversity of Groningen · NLUniversity of Milan · ITUniversity of Palermo · ITWestern University · CAWihuri Research Institute · FI

Funding

Systems genomics of metabolic syndrome traitsP01HL028481 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REUE, KAREN · 1985 to 2019
$50.2M
British Heart Foundation RG/08/008/25291CIHR CTP-79853CIHR MOP-13430CIHR MOP-79523NHLBI NIH HHS P01 HL028481
6 · The paper itself

Abstract

Plasma triglyceride concentration is a biomarker for circulating triglyceride-rich lipoproteins and their metabolic remnants. Common mild-to-moderate hypertriglyceridaemia is typically multigenic, and results from the cumulative burden of common and rare variants in more than 30 genes, as quantified by genetic risk scores. Rare autosomal recessive monogenic hypertriglyceridaemia can result from large-effect mutations in six different genes. Hypertriglyceridaemia is exacerbated by non-genetic factors. On the basis of recent genetic data, we redefine the disorder into two states: severe (triglyceride concentration >10 mmol/L), which is more likely to have a monogenic cause; and mild-to-moderate (triglyceride concentration 2-10 mmol/L). Because of clustering of susceptibility alleles and secondary factors in families, biochemical screening and counselling for family members is essential, but routine genetic testing is not warranted. Treatment includes management of lifestyle and secondary factors, and pharmacotherapy. In severe hypertriglyceridaemia, intervention is indicated because of pancreatitis risk; in mild-to-moderate hypertriglyceridaemia, intervention can be indicated to prevent cardiovascular disease, dependent on triglyceride concentration, concomitant lipoprotein disturbances, and overall cardiovascular risk.

Indexed as

Multifactorial InheritanceAnimalsBiomarkersCombined Modality TherapyGenetic Predisposition to DiseaseHealth PromotionHumansHypertriglyceridemiaLife StylePractice Guidelines as TopicTriglyceridesBiomarkersTriglycerides

Identifiers

PMID24731657
PMCPMC4201123
OpenAlexW2125012558

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.